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Abstract
Introduction: Hyperglycemia, hypoglycemia, and increased glycemic variability have each been independently
associated with increased risk of mortality in critically ill patients. The role of diabetic status on modulating the
relation of these three domains of glycemic control with mortality remains uncertain. The purpose of this
investigation was to determine how diabetic status affects the relation of hyperglycemia, hypoglycemia, and
increased glycemic variability with the risk of mortality in critically ill patients.
Methods: This is a retrospective analysis of prospectively collected data involving 44,964 patients admitted to 23
intensive care units (ICUs) from nine countries, between February 2001 and May 2012. We analyzed mean blood
glucose concentration (BG), coefficient of variation (CV), and minimal BG and created multivariable models to
analyze their independent association with mortality. Patients were stratified according to the diagnosis of diabetes.
Results: Among patients without diabetes, mean BG bands between 80 and 140 mg/dl were independently
associated with decreased risk of mortality, and mean BG bands >140 mg/dl, with increased risk of mortality.
Among patients with diabetes, mean BG from 80 to 110 mg/dl was associated with increased risk of mortality and
mean BG from 110 to 180 mg/dl with decreased risk of mortality. An effect of center was noted on the relation
between mean BG and mortality. Hypoglycemia, defined as minimum BG <70 mg/dl, was independently
associated with increased risk of mortality among patients with and without diabetes and increased glycemic
variability, defined as CV >20%, was independently associated with increased risk of mortality only among patients
without diabetes. Derangements of more than one domain of glycemic control had a cumulative association with
mortality, especially for patients without diabetes.
Conclusions: Although hyperglycemia, hypoglycemia, and increased glycemic variability is each independently
associated with mortality in critically ill patients, diabetic status modulates these relations in clinically important
ways. Our findings suggest that patients with diabetes may benefit from higher glucose target ranges than will
those without diabetes. Additionally, hypoglycemia is independently associated with increased risk of mortality
regardless of the patient’s diabetic status, and increased glycemic variability is independently associated with
increased risk of mortality among patients without diabetes.
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Introduction
Stress-induced hyperglycemia during intensive care unit
(ICU) admission has a strong and consistent relation
with mortality [1-3]. Nevertheless, hyperglycemia in
these populations of patients was not always treated
with insulin infusion until the publication of a landmark
single-center study in 2001 [4]. This trial demonstrated
reductions in mortality when continuous intravenous
insulin was used to achieve blood glucose (BG) from 80
to 110 mg/dl, compared with conventional therapy.
Although these findings were corroborated in a large
single-center cohort study [5], they were not confirmed
by subsequent randomized trials [6-10].
One possible explanation for the divergent results
among such trials may relate to the incidence of severe
hypoglycemia sustained by patients in the interventional
arms of randomized trials [6-11]. Data from observational
[12-17] and interventional studies [4,6,11] demonstrated
a strong and independent relation between hypoglycemia
and mortality, even at milder thresholds, such as BG <70
mg/dl. Glycemic variability, not considered in the design
or implementation of these trials, has also been indepen-
dently associated with mortality in observational [18-24]
and prospective [25] investigations. These findings have
led to the emergence of the concept that three domains
of glycemic control in the critically ill (hyperglycemia,
hypoglycemia, and glycemic variability [26,27]) must be
addressed to optimize glycemic control.
These factors, however, may not apply to all patients
and, in particular, to those with the diagnosis of diabetes,
presumably related to adaptive mechanisms developed in
the setting of chronic hyperglycemia [28]. Observational
cohort studies demonstrated that the relation between
hyperglycemia and mortality is much stronger among
patients without diabetes than in those with diabetes
[3,29-31], and other observational data suggested that
diabetes is not independently associated with increased
risk of mortality and may actually have a modest protec-
tive effect [32-36].
The purpose of this study was to assess how diabetic
status modulates the relation of the three domains of gly-
cemic control to mortality in a large and diverse group of
critically ill patients. We hypothesized that an association
would exist between mortality and each of the three
domains of glycemic control, but that a premorbid diag-
nosis of diabetes would attenuate the strength of these
associations compared with those observed in patients
without diabetes.
Materials and methods
Patient cohorts and clinical settings
Table 1 provides an overview of the nine different patient
cohorts (Amsterdam (AM), Austin (AU), BayCare (BC),
Birmingham (BI), Geelong (GE), Okayama (OK), Stamford
(ST), Tufts (TU), and Vienna (VI)), the organizational
structure of the ICUs, and the glycemic-control practices
of the different centers.
Outcomes
The primary end point for this analysis was all-cause
hospital mortality, defined as death before hospital
discharge.
Definitions and statistical analysis
Patients were classified as having preexisting diabetes by
documentation in their medical records. Disease severity
was assessed by using APACHE II scores [37]. Descrip-
tive statistics were calculated for all variables of interest.
Continuous variables were summarized by using means
and standard deviations, whereas categoric variables were
summarized by using counts and percentages.
The primary outcome, mortality, was assessed in rela-
tion to the glycemic-control metric and control variables
by using a logistic regression model adjusting for correla-
tion among observations taken at the same center (that is,
a generalized estimating equation (GEE) model. Three
models were run, one for each glycemic measure: hyper-
glycemia, hypoglycemia, and glycemic variability. The
models included a variable denoting diabetic status, the
glycemic measure, and the key interaction term of diabetic
status and glycemic measure. Each model controlled for
mean BG, age, APACHE II score, mechanical ventilation,
ICU length of stay (LOS), as well as adjusting for center
effects. The models on hyperglycemia and glycemic varia-
bility also controlled for hypoglycemia (minimum BG <70
mg/dl). Each model was stratified by diagnostic category:
medical or surgical. Patients admitted with trauma diag-
noses were included in the surgical cohort.
Before analysis, the set of variables was assessed for the
presence of multicollinearity. A tolerance statistic less
than or equal to 0.4 was considered to indicate the pre-
sence of multicollinearity, and in such cases, only one
member of a correlated set would be retained for the
multivariable model.
The estimates of each model were presented by using
odds ratios and their associated 95% confidence intervals.
A Bonferroni correction was applied to account for mul-
tiple testing. As the greatest number of pairwise compari-
sons presented for a glycemic-control variable was 10, the
standard P value of 0.05 was adjusted to 0.005 to denote
statistical significance for all analyses.
Analyses were run by using SAS Version 9.2 (SAS Insti-
tute, Cary, NC, USA) and MedCalc V12.4.0.0 (Ostend,
Belgium).
The institutional review boards of the different centers
approved the investigation. The requirement for informed
consent was waived because of the retrospective nature of
the study and because the data were deidentified.
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Table 1 Overview of cohorts
Amsterdam Austin BayCare Birmingham Geelong Okayama Stamford Tufts Vienna
Number of
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Table 1 Overview of cohorts (Continued)
Data
acquisition
The blood glucose levels
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In Table 2a and b, we present the considerable heteroge-
neity in baseline clinical characteristics of the nondiabetic
and diabetic cohorts in the nine different centers. The
percentage of patients with diabetes in the different cen-
ters ranged from 14.0% (AM) to 38.6% (BC).
Glycemic control
Patients with diabetes had higher mean BG, higher CV,
and higher rates of hypoglycemia than did patients with-
out diabetes. The nine centers demonstrated considerable
variation in the frequency of BG monitoring as well as in
the intensity of glycemic control, as reflected by mean BG.
Three domains of glycemic control: unadjusted mortality
data, nine centers
Mean BG
Figure 1A and 1B displays the unadjusted relation between
mean BG and mortality for the nine centers. Additional
file 1, Table S1 in the online supplement delineates the
number of patients in each “band” of mean BG, as well as
their mean (95% confidence interval (CI)) mortality.
Among patients without diabetes, mortality was lowest
when mean BG was 80 to 110 and 110 and 140 mg/dl and
increased at higher levels. The mortality rate of the 200
patients with mean BG <80 mg/dl (0.62% of the total of
32,084 patients without diabetes) was 47.0%. Among
patients with diabetes, the shape of the relation between
mean BG and mortality was characterized as a shallow
trough, with modestly higher mortality in the aggregate
with mean BG 80 to 110 and >180 mg/dl than with mean
BG in the 110- to 180-mg/dl range. The mortality rate of
the 71 patients with mean BG <80 mg/dl (0.55% of the
total of 12,880 patients with diabetes) was 42.3%.
Hypoglycemia
Figure 2A and 2B illustrates the unadjusted relation
between hypoglycemia and mortality. Hypoglycemia was
associated with increased mortality in patients with dia-
betes as well as in patients without diabetes, although the
relation was stronger among patients without diabetes.
Glycemic variability
Figure 3A and 3B displays the unadjusted relation
between CV and mortality. Among patients without dia-
betes, the relation between increasing CV and increasing
mortality was steep, with more than a threefold higher
mortality among the entire cohort with CV >40% com-
pared with those with CV <20%. This relation was simi-
lar, albeit attenuated, among patients with diabetes.
Cumulative derangements in the three domains of
glycemic control and their association with mortality
Figure 4A and 4B illustrates the cumulative impact of
derangements in the three domains of glycemic control.
Among patients without diabetes who had mean BG
between 80 and 110, 110 and 140, and 140 and 180 mg/
dl, increasing CV and the occurrence of hypoglycemia
were associated with increased mortality, and their effect
was cumulative. Among patients without diabetes with
mean BG >180 mg/dl, no incremental impact was found
of additional derangements of glycemic control. Among
patients with diabetes, hypoglycemia was consistently
associated with increased mortality, but mean BG and
CV did not have a consistent, cumulative impact on
mortality.
Multivariable analysis
Figure 5A through F displays the results of multivariable
analysis, assessing the independent association of bands
within each domain with mortality.
Mean BG
An effect of center was seen on the relation between
mean BG and mortality. Among patients without dia-
betes, mean BG of 110 to 140 mg/dl was independently
associated with reduced risk of mortality compared with
mean BG of 140 to 180 and >180 mg/dl, and similar risk
compared with mean BG of 80 to 110 mg/dl.
The medical and surgical patients demonstrated differ-
ent patterns. Among medical patients, bands of mean BG
of 80- to 140-mg/dl range were independently associated
with the lowest risk of mortality, with increased risk of
mortality at higher bands. In contrast, among surgical
patients, a mean BG of 80 to 110 mg/dl was indepen-
dently associated with increased risk of mortality com-
pared with bands of mean BG of 110 to 180 mg/dl.
The relation of mean BG to mortality was somewhat
different among patients with diabetes. Among the entire
cohort of patients with diabetes, as well as for both medi-
cal and surgical subpopulations, mean BG of 80 to 110
mg/dl was independently associated with increased risk
of mortality compared with the bands of mean BG of 110
to 180 mg/dl, those with mean BG of 110 to 140, 140 to
180, and <180 mg/dl had a reduced risk of mortality.
Hypoglycemia
Severe (minimum BG <40 mg/dl) and mild to moderate
(BG of 40 to 69 mg/dl) hypoglycemia were indepen-
dently associated with increased risk of mortality, for
the entire cohort, as well as for the medical and surgical
subpopulations.
Glycemic variability
Among patients without diabetes, low glycemic variability
(CV <20%) was independently associated with decreased
risk of mortality compared with bands of CV of 20% to
40% and >40% for the entire cohort; this relation was
more robust in medical patients than in surgical patients.
However, among patients with diabetes, multivariable
analysis demonstrated that increased CV was not inde-
pendently associated with increased risk of mortality.
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Table 2 Baseline characteristics, selected outcomes, and details of glycemic control
a. Nondiabetes patients
ALL Amsterdam Austin BayCare Birmingham Geelong Okayama Stamford Tufts Vienna
Number 32,084 1,427 899 12,111 4,478 3,944 2,494 3,928 1,657 1,146
Age (years) 64 (50-77) 62 (48-72) 63 (49-75) 67 (52-80) 59 (43-70) 69 (57-77) 61 (39-73) 67 (51-80) 59 (46-73) 58 (46-68)
Male (%) 56.4 62.6 61.8 50.8 61.0 61.9 58.6 N/A 57.5 60.9
Patient type (%)
Medical 56.8 37.0 55.6 81.2 30.8 35.3 32.1 52.0 70.1 80.9
Surgical 43.2 63.0 44.4 18.8 69.2 64.7 67.9 48.0 29.9 19.1
Ventilation (%) 41.3 84.2 69.5 27.6 26.3 69.8 53.5 37.2 39.4 77.8
APACHE II 19.0 (8.3) 19.0 (7.2) 16.2 (7.4) 23.4 (7.3) 13.8 (5.9) 16.2 (6.5) 13.5 (4.6) 15.6 (8.9) 15.5 (7.4) 16.0 (8.5)
ICU LOS 2.8 (1.6-5.2) 1.9 (1.0-3.9) 2.0 (1.1-4.0) 3.1 (2.0-5.1) 4.1 (2.2-8.0) 1.8 (1.0-2.9) 4 (3-7) 1.7 (0.9-3.5) 2.9 (1.8-5.4) 6 (3-11)
Mortality (%) 12.8 14.8 13.6 12.8 13.8 11.6 5.5 14.4 10.4 21.3
Glycemic control








































Min BG <40 2.4 1.3 0.6 3.9 1.2 0.8 0.2 2.2 2.4 7.8
MIN BG 40-69 12.6 12.5 8.6 12.2 7.7 5.5 2.2 18.7 11.8 34.1
NO HYPO 85.0 86.2 90.8 84.9 91.1 93.7 97.6 79.1 85.8 58.1
Number BG 10 (5-21) 12 (7-28) 12 (7-23) 8 (4-17) 14 (7-31) 9 (6-16) 7 (4-18) 13 (7-29) 10 (5-21) 22 (11-49)
BG/24 hoursa 4.5 7.0 5.7 3.5 3.9 5.5 2.8 9.0 4.3 4.5
b. Diabetes patients
ALL Amsterdam Austin BayCare Birmingham Geelong Okayama Stamford Tufts Vienna
Number 12,880 233 278 7,626 1,051 618 1,043 1,104 633 294
Age (years) 68 (59-79) 66 (60-75) 67 (59-75) 70 (59-79) 65 (56-73) 66 (57-74) 67 (57-75) 70 (61-80) 69 (57-77) 65 (56-74)
Male (%) 56.4 67.4 64.7 53.1 64.3 59.3 65.3 N/A 56.2 61.6
Patient type (%)
Medical 70.2 39.5 54.0 85.0 38.4 45.1 28.1 63.0 75.3 77.9
Surgical 29.8 60.5 46.0 15.0 61.6 54.9 71.9 37.0 24.7 22.1
Ventilation (%) 30.9 83.7 73.0 23.1 17.6 58.0 48.1 39.9 38.5 77.8
APACHE II 21.9 (8.1) 21.1 (7.4) 17.8 (7.0) 24.4 (7.3) 16.0 (5.7) 16.7 (7.4) 15.1 (4.4) 18.5 (8.8) 17.0 (7.8) 16.5 (8.2)
ICU LOS 2.8 (1.6-5.0) 1.9 (1.0-3.9) 2.0 (1.1-4.4) 2.8 (1.7-4.8) 4.1 (2.3-8.0) 1.8 (1.0-3.5) 4 (3-7) 1.9 (1.0-4.2) 2.5 (1.5-5.0) 6 (3-11)
Mortality (%) 13.3 15.5 10.8 12.4 17.7 11.9 8.8 16.7 16.0 22.1
Glycemic control








































Min BG <40 5.4 4.3 1.4 7.1 3.4 3.1 1.0 6.1 4.7 13.3
Min BG 40-69 19.6 19.4 14.4 19.1 10.5 23.3 3.6 31.1 15.2 38.8
No hypo 75.0 76.6 84.2 73.8 86.1 73.6 95.4 62.8 80.1 47.9
Number BG 12 (6-26) 14 (8-31) 13 (9-29) 11 (6-23) 16 (8-32) 11 (7-20) 9 (4-21) 17 (8-42) 12 (6-30) 22 (12-54)
BG/24 hoursa 5.5 8.2 6.4 5.3 4.1 5.6 2.9 10.6 7.5 4.9
a. Okayama cohort: Age, Patient type, APACHE II score, Ventilation (%), ICU LOS based on subset of 260 patients. Birmingham cohort: APACHE II score based on
subset of 483 patients. b. Okayama cohort: Age, Patient type, APACHE II score, Ventilation (%), ICU LOS based on subset of 837 patients. Birmingham cohort:
APACHE II score based on subset of 2,516 patients. aCalculated as mean BG values/mean ICU LOS.
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Diabetes
Diabetes was independently associated with decreased
risk of mortality for the entire cohort (OR (95% CI))
0.93 (0.87 to 0.97); P = 0.0030. Figure 6 displays the
results of multivariable analysis assessing the indepen-
dent association of diabetes with mortality, stratified by
individual bands of the three domains of glycemic con-
trol. Among patients with mean BG of 80 to 110 mg/dl,
diabetes was independently associated with increased
risk of mortality for the entire cohort and the medical
subgroup of <80 to >110 mg/dl. However, for all other
bands of mean BG, diabetes was associated with
decreased risk of mortality for the entire cohort and the
medical subgroup. Diabetes was not independently asso-
ciated with mortality in the surgical subgroup. Similarly,



































































Figure 1 Mean blood glucose (BG) and mortality. The relation of mean BG (milligrams per deciliter) during ICU stay to mortality in those
without (A) and those with diabetes (B), for each of the nine cohorts as well as the entire population.
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Figure 2 Minimum BG and mortality. The relation of minimum BG (milligrams per deciliter) during ICU to mortality in nondiabetes (A) and
diabetes (B) patients, for each of the nine cohorts as well as the entire population. Cohorts with fewer than 20 patients in a particular “band”
are not reported.
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medical subgroup with hypoglycemia, diabetes was inde-
pendently associated with decreased mortality; diabetes
was not independently associated with mortality among
hypoglycemic surgical patients.
Finally, diabetes was independently associated with
decreased mortality among the entire cohort and both
subgroups in patients with increased glycemic variability,



































































Figure 3 Coefficient of variation and mortality. The relationp of coefficient of variation (%) to mortality in nondiabetes (A) and diabetes (B)
patients for each of the nine cohorts as well as the entire population. Cohorts with fewer than 20 patients in a particular “band” are not
reported.
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Figure 4 Cumulative derangements of three domains. The relation of cumulative derangements of the three domains of glycemic control to
mortality in nondiabetes (A) and diabetes (B) patients. Patients are stratified first by mean BG during ICU stay, then by increasing coefficient of
variation (CV), and then by the presence or absence of hypoglycemia, defined as minimum BG <70 mg/dl during ICU stay. “Bands” with fewer
than 20 patients are not reported.
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Figure 5 Forest plots of bands of the independent association of mean BG, hypoglycemia, and coefficient of variation to mortality,
for diabetes and nondiabetes patients. This figure illustrates the independent association of mean BG, hypoglycemia, and coefficient of
variation to mortality, for diabetes and nondiabetes patients, including stratification based on medical versus surgical status. Pair-wise
comparisons of odds ratio (95% CI) for each domain of glycemic control are presented.
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Figure 6 Forest plots describing the independent association of diabetes with mortality, for each of the three domains of glycemic
control. This figure illustrate the independent association of diabetic status with mortality associated with each of the three domains of
glycemic control. For example, Figure 6a demonstrates that, among patients with mean BG 80 to 110 mg/dl, diabetes was independently
associated with increased risk of mortality, but among patients with mean BG of 110 to 140 mg/dl, diabetes was independently associated with
decreased risk of mortality.
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Discussion
Salient findings
This multicenter investigation demonstrates clinically
important differences between critically ill patients with
diabetes and patients without diabetes in regard to the
relation between the three domains of glycemic control
and mortality. Among patients without diabetes, the low-
est mortality occurred in patients with mean BG of 80 to
140 mg/dl. In contrast, among patients with diabetes,
mean BG of 80 to 110 mg/dl was independently asso-
ciated with increased risk of mortality compared with
patients with a mean BG of 110 to 140, 140 to 180, and
even >180 mg/dl. Hypoglycemia was independently asso-
ciated with increased risk of mortality among patients
with diabetes as well as among those without diabetes.
Increased glycemic variability (CV >20%), however, was
independently associated with increased risk of mortality
among patients without diabetes but not among patients
with diabetes. Derangements in more than one domain
of glycemic control were associated with cumulative
increase in mortality among nondiabetes patients but not
among patients with diabetes. Finally, for the entire
cohort of 44,964 patients, diabetes was independently
associated with decreased risk of mortality.
Relation to prior literature
Hyperglycemia is associated with increased mortality in
the critically ill [2,3,14,29-31]. Increments of mean BG
levels above 80 mg/dl are clearly associated with increas-
ing mortality among patients without diabetes. In con-
trast, a blunted relation exists between increasing mean
BG levels above 80 mg/dl and mortality among patients
with diabetes [3,29-31]. It is likely that changes in glyce-
mic-control practice over time have altered the observed
relation between mean BG and mortality. The current
investigation reflects contemporary practice; all patients
were admitted to ICUs practicing at least “moderate” gly-
cemic control; the range of mean BG values of the
patients without diabetes in the different centers (119 to
137 mg/dl) contrasts sharply with the mean morning BG
of the patients in the control arm of the first Leuven trial
of IIT (153 mg/dl) [4].
Hypoglycemia was the second of the three domains to
be associated with increased risk of mortality in critically
ill patients. Although most of the literature has described
an independent association of severe hypoglycemia (mini-
mum BG <40 mg/dl) with mortality [12-15,22], recent
observational studies [16,17] and prospective trial data
[11] have identified mild hypoglycemia (minimum BG <70
mg/dl) as being independently associated with increased
risk of mortality. Our findings confirm these observations
for patients with and without diabetes.
Glycemic variability was the third of the three domains to
be independently associated with mortality in the critically
ill [18-25]. One observational study suggested that glycemic
variability was independently associated with mortality only
among critically ill patients without diabetes [24]; our study
confirms these findings.
Finally, the independent impact of diabetic status,
without reference to glycemic control, on the mortality
of critically ill patients has been the subject of recent
observational studies that concluded that patients with
diabetes did not experience higher mortality, and dia-
betes may, in fact, be protective [30-36]. We demon-
strated here that diabetes is independently associated
with decreased risk of mortality.
Strengths and weaknesses
The clearest strength of this study is its size. The 44,964
patients include patients admitted with a large array of
medical, surgical, and trauma diagnoses, treated with a
variety of glycemic-control protocols, substantially
enhancing the generalizability of the investigation.
Moreover, this is a modern cohort of patients treated in
an era characterized by attention to glycemic control.
Each of the nine centers maintained a robust database
characterized by prospective data collection, creating an
additional important strength of this investigation: the
breadth of demographic, clinical outcome, and glycemic
data available for analysis. The absence of information
about insulin therapy is an important limitation. It is
likely that important differences exist between insulin-
treated and insulin-naive patients regarding the relation
of the three domains of glycemic control to mortality.
Another potential limitation is that the identification
of diabetic status was made on clinical grounds, based
on all information available at the time of ICU admis-
sion. It is likely that some patients designated as without
diabetes may actually have had diabetes; HgbA1c levels
were not obtained routinely, and, of course, glucose-tol-
erance testing could not be performed. Furthermore, we
are unable to determine whether the diabetes patients
were categorized as type I or type II. Although most
were likely type II, important differences may exist
between the two groups in their response to derange-
ments in the domains of glycemic control. Additionally,
we cannot provide details of nutritional therapy and
cannot therefore analyze the interactions among glyce-
mic control, nutritional therapy, and insulin treatment
of hyperglycemia. Moreover, many of the glycemia data
from several of the centers included in this study were
derived from capillary blood measured on point-of-care
devices, a method associated with increased analytic
inaccuracy [38-41]. Nevertheless, any degree of measure-
ment imprecision would only serve to dampen the
observed relations between glycemia and diabetic status.
Finally, we acknowledge that the observational nature
of this investigation mandates that its conclusions must
Krinsley et al. Critical Care 2013, 17:R37
http://ccforum.com/content/17/2/R37
Page 13 of 17
be considered to be hypothesis generating, rather than
proof of causality. Nevertheless, it would be unethical to
randomize patients to induced hyperglycemia, hypogly-
cemia, or increased glycemic variability.
Biological plausibility
Considerable evidence suggests that diabetes may alter
the relation between glycemia and mortality in critically
ill patients [28]. Diabetes patients may develop a toler-
ance to hyperglycemia, and a moderate degree of hyper-
glycemia that might exert toxicity in a patient without
diabetes may be well tolerated in a patient with diabetes.
This may explain the strong relation seen between
increasing mean BG levels and mortality in patients with-
out diabetes, detailed in several large observational stu-
dies, but not among those with diabetes [3,29-31,36,42].
In a recent study [43], diabetes patients with poor pread-
mission glycemic control, reflected by high HgbA1c
levels, had higher mortality when mean BG was tightly
controlled during ICU stay compared with patients with
high premorbid HgbA1c levels who had a higher mean
BG during ICU stay. These intriguing data parallel the
results of large interventional studies in outpatient popu-
lations with type II diabetes [44,45]. An extensive body of
literature has explored the physiological basis of the dele-
terious impact of hypoglycemia [46-51] demonstrated in
interventional [4,6,11,25] and observational [12-17] stu-
dies; none of these has focused explicitly on the different
impact that hypoglycemia may exert on patients with dia-
betes compared with those without diabetes. Similarly,
although various physiological mechanisms underlying
the harmful effect of increased glycemic variability
detailed in interventional [4,6,25] and observational
[18-24] studies have been proposed [52-56], the reasons
that glycemic variability has no or a muted independent
association with risk of mortality in patients with diabetes
compared with the striking relation seen in patients with-
out diabetes requires further clarification.
Clinical implications
The central findings of the current investigation have
important implications for the care of critically ill
patients. Hyperglycemia does not have the same associa-
tion with mortality among critically ill patients without
diabetes compared with those with diabetes. The eugly-
cemic range was independently associated with the low-
est risk of mortality among patients without diabetes
but with higher mortality among patients with diabetes.
Additionally, important differences were noted when
comparing medical and surgical populations. These find-
ings call into question the “one size fits all” strategy for
glycemic control of critically ill patients. It may be most
appropriate to establish lower glycemic target ranges for
medical patients without diabetes than for patients with
diabetes or for surgical patients without diabetes.
In addition, our observations call into question the
appropriateness of recently published glycemic-control
guidelines that recommend a glycemic target range of
140 to 180 mg/dl [57] or 140 to 200 mg/dl [58] for all cri-
tically ill patients. Furthermore, premorbid glycemic con-
trol in diabetes may have an important impact on the
consequences of glycemic control in the ICU [43]. The
optimal glycemic-control protocol may result not only
from stratifying patients by diabetic status, but also by
additionally stratifying patients with diabetes based on
the degree of preadmission glycemic control. In contrast,
the deleterious association of hypoglycemia with mortal-
ity, even at threshold levels of <70 mg/dl, was observed
in patients with diabetes and in those without diabetes.
Because hypoglycemia can never be the subject of a ran-
domized trial, the data from this investigation, when
combined with the findings from previous interventional
[4,6,10,11,25] and observational [12-17] studies, provide
the strongest evidence basis for the goal of avoiding
hypoglycemia in all critically ill patients.
Finally, increased glycemic variability, defined as CV
>20%, was identified in the current study as having a
strong independent association with increased risk of
mortality in patients without diabetes. These data provide
strong impetus for the creation of insulin-dosing strate-
gies and the development of new technologies [59] for
accurate continuous or near-continuous BG monitoring,
with the goal of reducing glycemic variability in critically
ill patients. Further investigation should stratify patient
outcomes by specific admitting diagnosis; important dif-
ferences may be found within the broad medical and sur-
gical categories that the current investigation was
underpowered to assess.
The design of future trials of IIT should include con-
sideration of all three domains of glycemic control as
well as recognition of the differences in their association
with mortality based on premorbid diabetes status.
Conclusions
This large international cohort study evaluated the relation
of diabetic status to the association of hyperglycemia,
hypoglycemia, and increased glycemic variability in a het-
erogeneous population of critically ill patients. We found
that diabetic status modulates the relation between the
three domains of glycemic control and mortality in clini-
cally important ways. Our findings suggest that patients
with diabetes may benefit from higher glucose target
ranges than those without diabetes. Additionally, hypogly-
cemia is independently associated with increased risk of
mortality, regardless of the patient’s diabetic status, and
increased glycemic variability is independently associated
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with increased risk of mortality among patients without
diabetes. These findings may inform the implementation
of glycemic-control protocols in the intensive care unit, as
well as for the design of future interventional trials of
intensive monitoring and treatment of dysglycemia in the
critically ill.
Key messages
• Diabetic status modulates the relation between the
three domains of glycemic control (hyperglycemia,
hypoglycemia, and glycemic variability) and mortality
in critically ill patients in clinically important ways.
• The range of mean BG from 80 to 140 mg/dl is
associated with the lowest severity adjusted mortality
among nondiabetes patients. In contrast, among
those with diabetes, a mean BG of 80 to 110 mg/dl
is associated with higher mortality risk than is the
range of 110 to 180 mg/dl.
• A single episode of hypoglycemia (BG <70 mg/dl) is
independently associated with increased risk of mortal-
ity among those without as well as those with diabetes.
• Increased glycemic variability, defined as CV >20%, is
independently associated with increased risk of mortal-
ity among those without, but not among those with
diabetes.
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